Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers by Yu, Zhenbao et al.
Published online 21 June 2007 Nucleic Acids Research, 2007, Vol. 35, No. 13 4535–4541
doi:10.1093/nar/gkm480
Aberrant allele frequencies of the SNPs located
in microRNA target sites are potentially associated
with human cancers
Zhenbao Yu
1,y, Zhen Li
1,2,y, Normand Jolicoeur
1,y, Linhua Zhang
1, Yves Fortin
1,
Edwin Wang
1, Meiqun Wu
1 and Shi-Hsiang Shen
1,2,*
1Health Sector, Biotechnology Research Institute, National Research Council of Canada, 6100 Royalmount
Avenue, Montre ´al, Que ´bec, Canada, H4P 2R2 and
2Department of Medicine, McGill University, Montre ´al,
Que ´bec, Canada, H3G 1A4
Received October 3, 2006; Revised May 11, 2007; Accepted May 31, 2007
ABSTRACT
MicroRNAs (miRNAs) are a class of noncoding
small RNAs that regulate gene expression by base
pairing with target mRNAs at the 30-terminal
untranslated regions (30-UTRs), leading to mRNA
cleavage or translational repression. Single-
nucleotide polymorphisms (SNPs) located at
miRNA-binding sites (miRNA-binding SNPs) are
likely to affect the expression of the miRNA target
and may contribute to the susceptibility of humans
to common diseases. We herein performed a
genome-wide analysis of SNPs located in the
miRNA-binding sites of the 30-UTR of various
human genes. We found that miRNA-binding
SNPs are negatively selected in respect to SNP
distribution between the miRNA-binding ‘seed’
sequence and the entire 30-UTR sequence.
Furthermore, we comprehensively defined the
expression of each miRNA-binding SNP in cancers
versus normal tissues through mining EST data-
bases. Interestingly, we found that some miRNA-
binding SNPs exhibit significant different allele
frequencies between the human cancer EST
libraries and the dbSNP database. More importantly,
using human cancer specimens against the
dbSNP database for case-control association stu-
dies, we found that twelve miRNA-binding SNPs
indeed display an aberrant allele frequency in
human cancers. Hence, SNPs located in miRNA-
binding sites affect miRNA target expression
and function, and are potentially associated with
cancers.
INTRODUCTION
MicroRNAs (miRNAs) are noncoding small ( 22nt)
RNAs that regulate the expression of target mRNAs (1,2).
MiRNAs are encoded in the chromosomal DNA and
transcribed as longer stem-loop precursors, termed pri-
miRNAs (3–5). Upon transcription, pri-miRNA is con-
verted to mature miRNA duplex through sequential
processing by the RNaseIII family of endonucleases
Drosha/DGCR8 and Dicer (3–5). One strand of the
processed duplex is incorporated into a silencing complex
and guided to target sequences located at the 30-terminal
untranslated regions (30-UTRs) of mRNAs by base
pairing (6), resulting in the cleavage of target mRNAs or
repression of their productive translation (6). Over the
past few years, several hundred miRNAs were identiﬁed
in animals and plants. It is currently estimated that
miRNAs account for  1% of the predicted genes in
higher eukaryotic genomes (7).
A growing body of evidence revealed that miRNAs
are involved in a variety of biological processes (8),
such as embryonic development, cell proliferation, cell
diﬀerentiation, apoptosis and insulin secretion. Moreover,
several reports indicate that miRNAs are involved in
human tumorigenesis. A systematic search for correlation
between the genomic position of miRNAs and the
location of cancer-associated regions revealed that over
half of the mapped miRNAs in chronic lymphocytic
leukemias (CLL) are located at fragile chromosome
regions involved in human cancers (9). MiRNA expres-
sion proﬁles also indicated that most miRNAs had
lower expression levels in tumors compared with normal
tissues (10). For example, Let-7, targeting the
oncogene RAS, is downregulated in lung cancers (11)
and miR-15 and 16, targeting the antiapoptotic factor
yThe authors wish to be known that, in their opinion, the first three authors should be regarded as joint First Authors.
*To whom correspondence should be addressed. Tel: +514 496 6318; Fax: +514 496 6319; Email: shi.shen@cnrc-nrc.gc.ca
Correspondence may also be addressed to Zhenbao Yu. Tel: +514 496 6377; Fax: +514 496 6319; Email: zhenbao.yu@nrc.ca
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.BCL2, are downregulated in CLL (12). Furthermore, a
germ-line mutation in the pri-miR-16-1/15a precursor was
found to cause its reduced transcription in a patient with
familial CLL (13).
Single-nucleotide polymorphisms (SNPs) are the most
frequent variation in the human genome, occurring once
every several hundred base pairs throughout the genome.
They have been studied extensively for deﬁning the regions
of disease candidate genes (14). Previously, in order
to search for SNP-aﬀected disease susceptibility and
outcome, most researchers focused on speciﬁc genes, as
resources and analytical tools were limited. Moreover,
until recently, there was a profound interest in nonsynon-
ymous SNPs because they shift the codons and often
change the protein structure and function. However, the
majority of SNPs in the genome are not nonsynonymous
SNPs that occur in untranslated, intronic or intergenic
regions. These SNPs could aﬀect complex diseases
through their eﬀect on gene expression quantitatively.
Unlike nonsynonymous SNPs, SNPs capable of aﬀecting
gene expression may not be easily identiﬁed because gene
regulatory elements could not be accurately deﬁned in a
complex gene regulation process. However, since the
thermodynamics of RNA–RNA binding plays an essential
role in miRNA interaction with target mRNA, it is
expected that sequence variations such as SNPs at
miRNA-binding sites may aﬀect the expression of
miRNA targets. The rationale for this assumption is
based on the principle of miRNA–target interaction.
Accumulating evidence revealed that 7nt at the
50-terminus of miRNAs from position 2 to position 8,
called ‘seed’ region, are essential for their function (15).
Based on these discoveries, several computational meth-
ods have been developed to predict miRNA targets
(16–23). Most of these methods have been biologically
validated and proved to be very eﬃcient and accurate. For
example, up to 90% of the randomly selected miRNA
targets predicted by Krek et al. (16) have been proved to
be true targets (24,25). The accuracy of these methods has
also been proved by gene expression proﬁling studies
(26,27). These methods have yielded a large number of
candidate targets in both plants and animals. The
estimated human miRNA targets can account for up to
one third of the human genes (16,20,24).
Consequently, a SNP located in the miRNA-binding
site of a miRNA target (called miRNA-binding SNP in
this study) is likely to disrupt miRNA–target interaction,
resulting in the deregulation of target gene expression.
In this regard, the eﬀect of this type of SNPs on gene
expression is predictable. Such SNP-associated deregula-
tion of the expression of an oncogene or tumor suppressor
might contribute to tumorigenesis. In this study, we
conducted a genome-wide search for SNPs located in
miRNA-binding sites of miRNA targets using the
dbSNP database and comprehensively deﬁned the display
of each SNP in cancers versus normal tissues through
mining the dbEST database. We thus identiﬁed a number
of miRNA-binding SNPs with apparent cancer-associated
aberrant allele frequencies, and conﬁrmed through geno-
typing that some of these SNPs are indeed aberrantly
present in tumors.
MATERIALS AND METHODS
Searching forSNPs located inthe whole30-UTRs and SNPs
complementary to the‘seed’ sequences ofmiRNAs in the
human genome
A3 0-UTR dataset and a miRNA target dataset of
human genes were obtained from UCSC Genome browser
(http://genome.ucsc.edu/cgi-bin/hgTables). The miRNA
target dataset, developed by Krek et al. (16), contains
the human genes, which, at 30-UTR, have a 7-nt segment
(called miRNA-binding ‘seed’ region here) complemen-
tary to the ‘seed’ region (the 7nt from position 2 to
position 8 at the 50-terminus) of human miRNAs.
A human SNP dataset (NCBI dbSNP Build 126) was
obtained from NCBI databases (ftp://ftp.ncbi.nih.
gov/snp). The genomic locations (chromosome number
and nucleotide position) on human chromosome of the
SNPs, the 30-UTRs and the miRNA-binding ‘seed’ regions
are all indicated in the individual datasets. The SNPs
located in the 30-UTRs and the SNPs located in the
miRNA-binding ‘seed’ regions of human genes were
identiﬁed using the chromosomal location information.
Allele distribution analysis of theSNPs located in
miRNA-targeting sitesin cancer EST libraries versus
dbSNP database
Human expressed sequence tag (EST) libraries and
EST sequences were obtained from NCBI databases
(http://www.ncbi.nlm.nih.gov/projects/dbEST/). The EST
libraries were manually curated and cataloged into cancer
EST libraries and normal tissue EST libraries. Totally,
2.2 millions of EST sequences were obtained from 3721
cancer EST libraries and 1.9 millions of EST sequences
from 2010 normal tissue EST libraries. MiRNA targets
predicted by Krek et al. (16) were obtained. The SNPs
located in the miRNA-binding regions ( 30-nt long),
called miRNA-binding SNPs, were identiﬁed by blast
searching for the dbSNP database using the miRNA target
sequences. The EST fragments representing each allele
of miRNA-binding SNPs were then identiﬁed by blast-
searching for the cancer EST libraries and normal tissue
EST libraries respectively, using a 30-nt sequence sur-
rounding the SNP site. The sequences for both alleles were
used separately for searching. Only the sequences with
100% identity were picked up. For each SNP, the total
number of ESTs corresponding to each allele identiﬁed
from the cancer EST libraries and from normal tissue EST
libraries were counted respectively and compared with the
number found in the dbSNP database. Fisher’s exact test
was used to determine the signiﬁcant diﬀerence of the
allele frequency of each SNP by comparing the cancer EST
libraries with that of the dbSNP database. The allelic
distributions of some miRNA-binding SNPs were found in
SNP500Cancer database (http://snp500cancer.nci.nih.gov/
home_1.cfm) that contains the allele frequency of the SNPs
of cancer-related genes in the four populations (28). We
also performed Fisher’s exact test in order to compare the
allele frequencies found in cancer EST libraries and each
population in the SNP500Cancer database.
4536 Nucleic Acids Research, 2007, Vol. 35, No. 13Determination of SNP allele frequencyin cancer patients
About 200 tumor tissue specimens from Caucasian
patients with various cancers were obtained from the
Cooperative Human Tissue Network (CHTN) in the
USA. Genomic DNAs were extracted from freshly frozen
specimens using DNeasy
R Tissue kit following the
manufacturer’s protocol (Qiagen). As controls, 1000
genomic DNAs of normal subjects were obtained from
the British 1958 birth cohort that is based on all persons
born in Britain during one week in 1958, and additional
200 genomic DNAs (Caucasian) were from Coriell
Institute for Medical Research. Collection and use of the
tissue and genomic DNA samples were approved by the
National Research Council Canada. For SNP allele
identiﬁcation,  300bp DNA fragments ﬂanking the
SNP of interest were ampliﬁed by PCR using the genomic
DNAs. The PCR products were puriﬁed using MinElute
96 UF plates (Qiagen) and subjected to genotyping
using one of the following methods. If one of the two
alleles of a SNP can be digested by a speciﬁc restriction
enzyme, a restriction enzyme digestion method was used.
Otherwise, DNA sequencing method was used. For
restriction enzyme digestion method, the digested PCR
products were analyzed by agarose gel electrophoresis,
which can distinguish the digested and undigested DNA
fragments, for calculation of allele frequencies.
RESULTS
SNPslocatedinthemiRNA-bindingmotifsofmiRNAtargets
are negatively selected at the30-UTRs of human genes
Although hundreds of miRNAs have been identiﬁed,
only a few of them have been functionally characterized,
thus the biological functions of miRNAs are largely
unknown. If the functions of miRNAs are, as assumed
currently, critical for basic biological processes, we expect
that the sequence variations, such as SNPs, in miRNA-
binding sites of miRNA targets should undergo a
purifying selection during evolution. To this end, we
downloaded the miRNA targets predicted by Krek et al.
(http://pictar.bio.nyu.edu/). Each of the predicted miRNA
targets contains at least one 7-nt segment (called ‘seed’
region here) at the 30-UTRs, which is crucial for the
recognition of miRNAs. The SNPs located in the ‘seed’
regions are most likely to aﬀect miRNA–target interaction
and thus target expression. We therefore searched for the
SNPs located in the ‘seed’ regions of human miRNA
targets using the dbSNP database (http://www.ncbi.nlm.
nih.gov/projects/SNP/). For comparison, we also searched
for the SNPs that are located in the whole 30-UTRs of
human genes in the same database. We counted the
density of the SNPs found in the miRNA-binding ‘seed’
regions (7nt/seed) versus the whole 30-UTRs. As shown in
Table 1, 265 SNPs from 1400000 nucleotides, namely
0.182 SNP/kb, were located in the miRNA-binding ‘seed’
regions of 200000 miRNA targets, whereas 20588 SNPs
from 96484523 nucleotides (the total number of nucleo-
tides at the 30-UTRs of human genes obtained for this
study), namely 0.213 SNP/kb, were identiﬁed in the whole
30-UTRs of human genes, indicating that SNPs arise less
frequently in the miRNA-binding sites of miRNA targets
than in the entire 30-UTR (P50.022). This result suggests
that SNPs at the miRNA-binding ‘seed’ regions are
negatively selected under evolutional pressure. Since
purifying selection (negative selection) eliminates the
mutations that have deleterious eﬀects on function,
the relative low density of miRNA-binding SNPs at the
30-UTRs of human genes supports the important role of
miRNA–target interaction.
MiRNA-binding SNPs display arareminor allele frequency
Since SNPs are mutations that occur throughout evolu-
tion, natural selection should limit the alleles that have
deleterious eﬀects on function with time and thus limit the
frequency of these harmful alleles. As shown in Figure 1,
we found that more than 70% of the miRNA-binding
SNPs have a minor allele frequency less than 0.5% in the
dbSNP database. This level is higher than the average level
of all SNPs found in the same dbSNP database ( 10 and
25% observed in the HapMap and ENCODE datasets,
respectively) and the expected distribution under the
standard neutral model ( 50%). This result further
conﬁrms the important biological function of miRNAs.
SNPsin themiRNA-binding motifs affects miRNA target
expression
To further conﬁrm the essential biological function of
miRNAs as elucidated above by the SNP density analysis,
we determined the expression variation of diﬀerent alleles
of miRNA-binding SNPs via mining the dbEST database.
Because the EST libraries were constructed from cDNAs,
the relative frequency of the two alleles for each SNP
Table 1. Comparison of the abundance of SNPs located in the
miRNA-binding sites versus all the 30-UTRs in the human genome
SNP number Base number SNP/kilobase P-value
30UTR 20588 96484523 0.213 0.022
miRNA target 265 1400000 0.182
Note: P-value was calculated using Fisher’s exact test.
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Figure 1. Distribution of the minor allele frequencies of miRNA-
binding SNPs. The number of each allele of a miRNA-binding SNP
found in the dbSNP database was counted and the frequency of the
minor allele (ratio of the number of minor allele to total number of the
two alleles) was calculated. The SNPs were then grouped according to
their minor allele frequencies.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4537found in the dbEST database should be similar to that
found in the dbSNP database, if the SNP does not aﬀect
gene expression. However, if a SNP aﬀects gene expres-
sion, the two alleles of this SNP are likely diﬀerentially
expressed and thus the relative frequency of the two alleles
present in the dbEST database might be diﬀerent
from that found in the dbSNP database. Since the 7-nt
‘seed’ region of a miRNA is the most important sequence
for miRNA–target interaction and miRNA function,
further analysis was conducted by focusing on these
regions. For convenience, we termed the allele of a
miRNA-binding SNP that has the sequence complemen-
tary to the ‘seed’ region of the miRNA as ‘target allele’
and the other with one mismatch as ‘non-target allele’.
Among the 930 miRNA-binding SNPs we identiﬁed,
297 are located in the miRNA-binding ‘seed’ regions.
Half of these 297 SNPs (129) have allele frequency data
available in the dbSNP database. We then calculated the
relative frequency of the target allele and the non-target
allele for each of these 129 SNPs in the dbEST database
and in the dbSNP database, respectively. We found
that 35 out of the 129 SNPs have a zero frequency of
non-target allele in both databases, indicating that the
non-target alleles (the minor alleles) of these SNPs are too
rare to be detected. Therefore, these 35 were not used
for comparison. However, 59 (63%) of the remaining 94
have a higher frequency of non-target alleles in the dbEST
database than in the dbSNP database, whereas only 35
(37%) of them have a higher frequency of non-target
alleles in the dbSNP database than in the dbEST database
(Table 2). More importantly, the average frequency ratio
of the non-target alleles over target alleles for these SNPs
is signiﬁcantly higher in the dbEST database than in the
dbSNP database (0.127 versus 0.086) (Table 2), suggesting
that the average expression level of the non-target alleles
of miRNA-binding SNPs is higher than that of the target
alleles. These results indicate that the SNPs/mutations
located in the miRNA-binding ‘seed’ regions of miRNA
targets can disrupt miRNA–target interaction and lead to
up-regulation of miRNA target expression.
Identification of miRNA targetswith aberrantSNP allele
frequencyin human tumors
To identify the miRNA-binding SNPs that may contribute
to cancer susceptibility, we carried out a genome-wide
scale in silico analysis of the dbSNP database in
conjunction with the human dbEST database. To do so,
we downloaded the human EST sequences derived from
both the cancer EST libraries and the normal tissue EST
libraries. In total, 2.2 million EST sequences from 3721
human cancer EST libraries and 1.9 million EST
sequences from 2010 human normal tissue EST libraries
were obtained. We then searched for the ESTs that
correspond to each allele of those SNPs located in the
miRNA-binding regions of miRNA targets in the cancer
EST libraries and in the normal tissue EST libraries
(Table S1). The miRNA targets were obtained from
Krek et al.’s report (16). A 30-nt segment for each
miRNA-binding site was entered in the original database
and used for SNP searching in this study. The allele
frequency of each SNP was also obtained from the dbSNP
database (Table S1). To determine whether the allele
frequency of these SNPs in the cancer EST libraries is
similar to or diﬀerent from that found in the general
population, we counted the number of ESTs for each
SNP allele found in cancer EST libraries and compared
it with that of the general population as found in
the dbSNP database. Fisher’s exact test was used to
determine the statistical signiﬁcance of the variations
observed (Figure 2). The SNPs above the horizontal line
of the ﬁgure have a P-value less than 0.01 ( log
(P-value)42, Figure 2).
Experimental validation ofmiRNA target SNPs withan
aberrant SNP allele frequency inhuman tumor tissues
The in silico analysis of the dbEST database and dbSNP
database provided us with some potential candidates
for miRNA-binding SNPs with an aberrant allele fre-
quency present in the human cancer EST database and
ﬁltered out many SNPs (the majority) that have similar
allele distribution in both databases. We next genotyped
genomic DNAs derived from human cancer tissues
in order to experimentally validate these potential
miRNA-binding SNPs. We compared the allele frequency
of each SNP found in cancer tissues with that found in the
Table 2. Comparison of allele frequency of miRNA-binding SNPs in
the dbEST database and in the dbSNP database
Number of SNPs with a higher frequency of the non-target
alleles in the dbEST database than in the dbSNP database
59
Number of SNPs with a higher frequency of the non-target
alleles in the dbSNP database than in the dbEST database
35
Average ratio of non-target allele frequency to target allele
frequency in the dbEST database
0.127
Average ratio of non-target allele frequency to target allele
frequency in the dbSNP database
0.086
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Figure 2. Comparison of the allele frequency of miRNA-binding SNPs
in the cancer EST libraries and in the dbSNP database. EST sequences
containing 30nt with 100% homology to one of the two SNP alleles
were identiﬁed from the cancer EST libraries. For each individual SNP,
the total number of ESTs with each allele was counted and compared
with that found in the dbSNP database. A Fisher’s exact test was
performed to determine the signiﬁcance of the diﬀerent distribution of
the two alleles in the cancer EST libraries versus the control population
found in the dbSNP database. The samples above the red line have a
P-value less than 0.01.
4538 Nucleic Acids Research, 2007, Vol. 35, No. 13dbSNP database and in the normal subjects. From 65
SNPs tested, we found that 12 have a signiﬁcantly
aberrant SNP allele frequency (P50.05) in human
cancer tissues as compared with the control present in
the dbSNP database (Table 3 and Table S2). The aberrant
allele frequencies of these SNPs were also found in
unaﬀected tissues, located near these cancer tissues
examined, suggesting their germ-line origin. Figure 3
shows the representative sequences of SNP rs16917496
derived from two colon tumor samples. To determine if
the number of SNPs (12 out of 65) that have an aberrant
allele frequency in cancer samples compared to the dbSNP
database is statistically signiﬁcant, we did genotyping
analysis of 16 of the 65 SNPs using normal subjects.
We found that none of the 16 SNPs have a signiﬁcant
diﬀerence of allele frequency in the normal subjects
from that in the dbSNP database (P40.1 for all of
them, Table S2), whereas 2 of the 16 SNPs have an
aberrant allele frequency in cancer population (Table S2,
rs1044129 and rs17107469). These results suggest that
the in silico analysis method provides us with useful
preliminary data for the identiﬁcation of miRNA-binding
SNPs that may aﬀect miRNA target expression, possibly
leading to cancer susceptibility. These SNPs with aberrant
allele frequencies in cancer can be used as potential
tumor markers and drug targets for early cancer detection
and prevention.
DISCUSSION
Under the neutral theory of molecular evolution, the
majority of DNA variations observed in a population are
due to random drift of neutral or nearly neutral
mutations. Natural selection, such as purifying selection,
may eliminate those mutations that have deleterious
eﬀects on function. This will reduce the ratio of those
mutations over neutral mutations observed in the present
population. In this study, we ﬁrst found that SNP density
is lower in the miRNA-binding motifs (‘seed’ regions)
than in the 30-UTRs, potentially caused by purifying
selection. In addition, since SNPs are the result of
mutations that occurred one time in human history,
natural selection may also lead to rare allele frequencies of
the mutations that could not be completely eliminated
under rapid population expansion, despite their deleter-
ious eﬀects on function. Indeed, we found that the
frequencies of the minor alleles (non-target alleles) of the
miRNA-binding SNPs are extremely low (0.079) based on
Figure 3. Representative sequencing results of two colon tumor samples
validating the aberrant allele frequency of SNP rs16917496. (A)A
colon tumor sample displays a normal homozygous T/T allele. (B)A
colon tumor sample displays a heterozygous T/G allele. Arrows
indicate the SNP position.
Table 3. MiRNA-binding SNPs with an aberrant SNP allele frequency in human tumor tissues
SNP miRNA target Count in dbSNP Count in cancers MAF (ctrl) MAF (case) Odds ratio
[95% CI]
P-value
Gene name Gene ID Major
allele
Minor
allele
Major
allele
Minor
allele
rs1044129
a RYR3 NM_001036 250 118 208 172 0.3207 0.4526 1.75 [1.30, 2.36] 4.9 10
 10
rs4901706 C14orf101 NM_017799 644 4 346 18 0.0062 0.0495 8.37 [3.34, 21.00] 1.1 10
 5
rs12583 DAG1 NM_00493 375 225 162 46 0.3750 0.2212 0.47 [0.33, 0.68] 1.5 10
 5
rs1128665 STK40 NM_032017 353 15 356 0 0.0408 0 5.4 10
 5
rs16917496 SETD8 NM_020382 287 81 248 136 0.2201 0.3542 1.94 [1.41, 2.68] 5.5 10
 5
rs17703261 AFF1 NM_005935 62 26 336 48 0.2955 0.1250 0.34 [0.20, 0.58] 2.5 10
 4
rs1053667 KIAA0423 NM_015091 681 19 174 16 0.0271 0.0842 3.29 [1.72, 6.32] 1.0 10
 3
rs11337 GOLGA7 NM_00102296 690 14 310 18 0.0199 0.0549 2.86 [1.45, 5.66] 3.6 10
 3
rs14109 MATR3 NM_108834 596 12 362 20 0.0197 0.0524 2.74 [1.36, 5.53] 8.6 10
 3
rs3660 KRT81 NM_002281 385 281 175 177 0.4219 0.5028 1.39 [1.07, 1.80] 0.014
rs17107469 SH2D4B NM_207372 326 0 188 4 0 0.0208 0.018
rs10463 USP9X NM_001039590 478 26 171 19 0.0516 0.1000 2.04 [1.11, 3.74] 0.025
*Fisher’s exact test was used to calculate the P-values based on the minor allele frequencies found in the human tumor specimens against the total
Caucasian subjects present in the dbSNP database. Minor allele frequencies (MAF) and odds ratios with 95% conﬁdence intervals (95% CI) are
shown for each SNP except rs1128665 and rs17197469, the counts of the minor alleles of which are zero.
aThe minor allele of rs1044129 is ‘A’ and the major allele is ‘G’ in the dbSNP database, but ‘G’ is the minor allele and ‘A’ is the major allele in the
cancer samples. The minor allele frequency (MAF) shown in the table for this SNP is the frequency of ‘A’ in dbSNP and the frequency of ‘G’ in the
cancer population. The frequency of ‘A’, which is 0.32 in the dbSNP database and 0.55 in the cancer population, was used to calculate odds ratio.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4539the dbSNP database analysis, which may reﬂect the
deleterious eﬀect of nucleotide substitutions at miRNA-
binding sites. Taken together, both the negative selection
(lower density) and the rare allele frequencies of miRNA-
binding SNPs at the miRNA-binding sites, reﬂect the
importance of miRNAs.
Rare SNP alleles may have severe consequences and
thus cause various human diseases. By mining the
dbEST database and dbSNP database, we identiﬁed a
number of miRNA-binding SNPs that have aberrant allele
frequency in the cancer EST libraries. However, using
EST libraries for this analysis has some limitations caused
by the quality of the EST sequences, biased sampling
and biased ethnic origin. To reduce the eﬀect of these
limitations on the accuracy of the results, we performed
further analysis. First, we manually searched for these
interesting miRNA target genes that have an aberrant
allele frequency in the cancer EST libraries compared to
that in the dbSNP database, as identiﬁed from the in silico
screen. We manually detected the quality of each EST
sequence to ensure that only the ESTs with high quality
are used for our ﬁnal statistical analysis of these
interesting SNPs. In addition, to determine the eﬀect of
EST quality on the results, we searched for the EST
sequences that contain any two other nucleotides (‘non-
SNP’ nucleotides) to replace the deﬁned SNP alleles at the
SNP position. We assumed that any EST sequence with
the substitution of two other ‘non-SNP’ nucleotides was
caused by sequencing errors and that the number of
sequencing errors causing change of one SNP allele to the
other SNP allele is similar to the number of errors
leading to the change of a SNP allele to a ‘non-SNP’ allele
(non-existing allele). Using these data, we can calculate the
contribution of EST sequence quality to the errors of SNP
allele distribution. We found that among 18845 ESTs
located in the two SNP alleles, 24 ESTs were substituted
by the ‘non-SNP’ nucleotides, revealing a 0.13% error in
our analysis (0.65% for the minor alleles and 0.07% for
the major alleles, Table 4). To reduce sampling bias,
we counted only one EST for a speciﬁc allele of a SNP if
more than one EST for the allele were found in the same
library. However, many diﬀerent EST libraries might be
constructed with the cDNAs derived from the same
donor. EST sequences representing a speciﬁc SNP allele
found in diﬀerent libraries derived from the same donor
may be counted several times although only one count
should be used for statistical analysis. We could not avoid
this kind of sampling bias since the identity of donors for
the EST library was not available. For the same reason,
it is hard to exclude the eﬀect of bias of ethnic origin.
Nevertheless, to reduce the limitation caused by the lack
of information of the ethnic origin of donors in our
statistical analysis, we ﬁrst compared the allele frequency
found in the cancer EST database with that of the dbSNP
database from all four populations and also with that
from each individual population, if data from diﬀerent
populations was available. In addition, we used the
SNP500Cancer database where the SNP allele frequency
data from all four populations are available (Table S3).
In spite of these limitations, we assessed the eﬃcacy of in
silico analysis through experimental studies using human
cancer samples. We successfully conﬁrmed by experimen-
tal validation 12 out of 65miRNA-binding SNPs with
an aberrant allele frequency in the cancer EST libraries.
These results indicate that the aberrant allele frequencies
of the miRNA-binding SNPs present in tumors, might
be an important factor contributing to tumorigenesis.
In addition, these results demonstrated the usefulness of
the primary in silico analysis, as it was able to ﬁlter out the
majority of the miRNA-binding SNPs that showed no
diﬀerence of allele frequencies between the cancer EST
database and the dbSNP database.
SUPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank Denis L’Abbe for technical assistance and
Dr Krikor Bijian for comments on the manuscript.
We acknowledge use of DNA from the British 1958
Birth Cohort collection, funded by the Medical Research
Council grant G0000934 and the Wellcome Trust grant
068545/Z/02, and thank D. Strachan, R. Jones and all
other members of the 1958 Cohor Biomedical Study
Team. This work was supported in part by the Canadian
Institute of Health Research Grant MOP82807. Funding
to pay the Open Access publication charges for this article
was provided by the National Research Council Canada.
Conﬂict of interest statement. None declared.
REFERENCES
1. Ambros,V. (2001) microRNAs: tiny regulators with great potential.
Cell, 107, 823–826.
2. Bartel,D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism,
and function. Cell, 116, 281–297.
3. Cullen,B.R. (2004) Transcription and processing of human
microRNA precursors. Mol. Cell, 16, 861–865.
4. Kim,V.N. (2005) MicroRNA biogenesis: coordinated cropping and
dicing. Nat. Rev. Mol. Cell Biol., 6, 376–385.
5. Carmell,M.A. and Hannon,G.J. (2004) RNase III enzymes and the
initiation of gene silencing. Nat. Struct. Mol. Biol., 11, 214–218.
6. Meister,G. and Tuschl,T. (2004) Mechanisms of gene silencing by
double-stranded RNA. Nature, 431, 343–349.
7. Griﬃths-Jones,S., Grocock,R.J., van,D.S., Bateman,A. and
Enright,A.J. (2006) miRBase: microRNA sequences, targets and
gene nomenclature. Nucleic Acids Res., 34, D140–D144.
8. Ambros,V. (2004) The functions of animal microRNAs. Nature,
431, 350–355.
Table 4. Contribution of EST sequence quality to the errors of the
analysis
Major alleles Minor alleles Non-SNP alleles
Number of ESTs 17016 1829 24
Percentage of errors
  0.07% 0.65%
0.13%
*Errors were calculated as:
24/(17016+1829) 100%=0.13%;
(24/2)/17016 100%=0.07%;
(24/2)/1829 100%=0.65%.
4540 Nucleic Acids Research, 2007, Vol. 35, No. 139. Calin,G.A., Sevignani,C., Dumitru,C.D., Hyslop,T., Noch,E.,
Yendamuri,S., Shimizu,M., Rattan,S., Bullrich,F. et al. (2004)
Human microRNA genes are frequently located at fragile sites and
genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA,
101, 2999–3004.
10. Lu,J., Getz,G., Miska,E.A., Alvarez-Saavedra,E., Lamb,J., Peck,D.,
Sweet-Cordero,A., Ebert,B.L., Mak,R.H. et al. (2005)
MicroRNA expression proﬁles classify human cancers. Nature, 435,
834–838.
11. Takamizawa,J., Konishi,H., Yanagisawa,K., Tomida,S., Osada,H.,
Endoh,H., Harano,T., Yatabe,Y., Nagino,M. et al. (2004) Reduced
expression of the let-7 microRNAs in human lung cancers in
association with shortened postoperative survival. Cancer Res., 64,
3753–3756.
12. Calin,G.A., Dumitru,C.D., Shimizu,M., Bichi,R., Zupo,S., Noch,E.,
Aldler,H., Rattan,S., Keating,M. et al. (2002) Frequent deletions
and down-regulation of micro- RNA genes miR15 and miR16at
13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA,
99, 15524–15529.
13. Calin,G.A., Ferracin,M., Cimmino,A., Di,L.G., Shimizu,M.,
Wojcik,S.E., Iorio,M.V., Visone,R., Sever,N.I. et al. (2005) A
microRNA signature associated with prognosis and progression in
chronic lymphocytic leukemia. N. Engl. J. Med., 353, 1793–1801.
14. Bernig,T. and Chanock,S.J. (2006) Challenges of SNP genotyping
and genetic variation: its future role in diagnosis and treatment of
cancer. Expert. Rev. Mol. Diagn., 6, 319–331.
15. Brennecke,J., Stark,A., Russell,R.B. and Cohen,S.M. (2005)
Principles of microRNA-target recognition. PLoS Biol., 3, e85.
16. Krek,A., Grun,D., Poy,M.N., Wolf,R., Rosenberg,L., Epstein,E.J.,
MacMenamin,P., da Piedade,I., Gunsalus,K.C. et al. (2005)
Combinatorial microRNA target predictions. Nat. Genet., 37,
495–500.
17. Enright,A.J., John,B., Gaul,U., Tuschl,T., Sander,C. and
Marks,D.S. (2003) MicroRNA targets in Drosophila. Genome Biol.,
5, R1.
18. John,B., Enright,A.J., Aravin,A., Tuschl,T., Sander,C. and
Marks,D.S. (2004) Human MicroRNA targets. PLoS Biol., 2, e363.
19. Kiriakidou,M., Nelson,P.T., Kouranov,A., Fitziev,P.,
Bouyioukos,C., Mourelatos,Z. and Hatzigeorgiou,A. (2004) A
combined computational-experimental approach predicts human
microRNA targets. Genes Dev., 18, 1165–1178.
20. Lewis,B.P., Burge,C.B. and Bartel,D.P. (2005) Conserved seed
pairing, often ﬂanked by adenosines, indicates that thousands of
human genes are microRNA targets. Cell, 120, 15–20.
21. Rhoades,M.W., Reinhart,B.J., Lim,L.P., Burge,C.B., Bartel,B. and
Bartel,D.P. (2002) Prediction of plant microRNA targets. Cell, 110,
513–520.
22. Robins,H., Krasnitz,M., Barak,H. and Levine,A.J. (2005) A
relative-entropy algorithm for genomic ﬁngerprinting captures host-
phage similarities. J. Bacteriol., 187, 8370–8374.
23. Stark,A., Brennecke,J., Russell,R.B. and Cohen,S.M. (2003)
Identiﬁcation of Drosophila MicroRNA targets. PLoS Biol., 1, E60.
24. Rajewsky,N. (2006) MicroRNA target predictions in animals. Nat.
Genet., 38(Suppl.), S8–S13.
25. Stark,A., Brennecke,J., Bushati,N., Russell,R.B. and Cohen,S.M.
(2005) Animal microRNAs confer robustness to gene expression
and have a signiﬁcant impact on 30UTR evolution. Cell, 123,
1133–1146.
26. Lim,L.P., Lau,N.C., Garrett-Engele,P., Grimson,A., Schelter,J.M.,
Castle,J., Bartel,D.P., Linsley,P.S. and Johnson,J.M. (2005)
Microarray analysis shows that some microRNAs downregulate
large numbers of target mRNAs. Nature, 433, 769–773.
27. Krutzfeldt,J., Rajewsky,N., Braich,R., Rajeev,K.G., Tuschl,T.,
Manoharan,M. and Stoﬀel,M. (2005) Silencing of microRNAs
in vivo with ’antagomirs’. Nature, 438, 685–689.
28. Packer,B.R., Yeager,M., Burdett,L., Welch,R., Beerman,M., Qi,L.,
Sicotte,H., Staats,B., Acharya,M. et al. (2006) SNP500Cancer: a
public resource for sequence validation, assay development, and
frequency analysis for genetic variation in candidate genes. Nucleic
Acids Res., 34, D617–D621.
Nucleic Acids Research, 2007, Vol. 35, No. 13 4541